stars 1 stars 2 stars 3

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.

Enobia Pharma Questions

The Enobia Pharma annual revenue was $23.6 million in 2026.

4 people are employed at Enobia Pharma.

Enobia Pharma is based in Montreal, Quebec.

The NAICS codes for Enobia Pharma are [325, 3254, 32, 32541].

The SIC codes for Enobia Pharma are [283, 2834, 28].

Top Enobia Pharma Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users